In this multicentre noncomparative trial, 2523 patients with tonsillitis, sinusitis, bronchitis, pneumonia or acute exacerbations (superinfections) of chronic bronchitis received oral roxithromycin 150mg twice daily for a minimum of 5 days. A large proportion of patients had previously been unsuccessfully treated with antibiotic therapy for the presenting infections (35% of patients with tonsillitis, 43% of patients with sinusitis and 47% of patients with lower respiratory tract infections had been previously treated).
Overall, roxithromycin therapy was successful in 94% of patients, ranging from a 97.1% success rate in patients with pneumonia to one of 87.4% in patients with superinfections exacerbating chronic bronchitis. The median (± SD) duration of therapy was 6.7 ± 2.2 days in patients with lower respiratory tract infections, 6.1 ± 1.5 days in patients with tonsillitis and 6.3 ± 2.0 days in patients with sinusitis. Only 8.1% of patients required treatment for more than 9 days. Fever tended to resolve within a little over 2 days in those patients affected.
Roxithromycin was very well tolerated, with 95.7% of patients exhibiting no adverse effects and only 1.3% discontinuing therapy. Most adverse events resolved despite continued therapy.
Thus, roxithromycin is an effective and well tolerated oral treatment for infections of the upper and lower respiratory tracts.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Akoun G, Bertrand A, Caubarrère I, Constans P, Dumont R, et al. Clinical evaluation of roxithromycin (RU 28965) in the treatment of hospitalised patients with lower respiratory tract infections. In Butzler & Kobayashi (Eds) Macrolides: a review with an outlook on future developments, pp. 95–99, Excerpta Medica, Amsterdam, 1986
Blanc F, d’Enfant J, Fiessinger S, Lenoir A, Renault M, et al. An evaluation of tolerance of roxithromycin in adults. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 179–183, 1987
Ingram RH. Chronic bronchitis, emphysema, and airways obstruction. In Braunwald et al. (Eds) Harrison’s Principles of Internal Medicine 11th ed., pp. 1087–1095, McGraw-Hill, New York, 1987
Lerebourg-Pigeonniere G, d’Enfant J, Fiessinger S. Etude multicentrique de l’efficacité clinique et de la tolerance de la roxithromycin (Rulid) dans les infections respiratoires. Réunion Interdisciplinaire de Chimiothérapie Antiinfectieuse, Paris, December 3, 1987
Levin RH. Respiratory infections. In Herfindal ET & Hirschman JL (Eds) Clinical pharmacology and therapeutics 3rd ed., pp. 166–184, Williams & Wilkins, Baltimore, 1984
Matsumoto F, Hara K. Multicentre clinical studies of roxithromycin in respiratory, otorhinolaryngological, skin and dental infections and chlamydial sexually transmitted diseases. 15th International Congress of Chemotherapy, Istanbul, July 19–24, 1987
Weinstein L. Diseases of the upper respiratory tract. In Braunwald et al. (Eds) Harrison’s principles of internal medicine 11th ed., pp. 1111–1115, McGraw-Hill, New York, 1987
Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37: 8–14, 1989
For members of the Multicentre National Team, see p. 45
About this article
Cite this article
Higuera-Ramirez, F., Hidalgo, H. Multicentre Study of the Efficacy and Tolerability of Roxithromycin in the Treatment of Respiratory Tract Infections. Drug Invest 3, 38–46 (1991). https://doi.org/10.1007/BF03258334
- Chronic Bronchitis
- Drug Invest
- Lower Respiratory Tract Infection